| Literature DB >> 35625181 |
Said Abukhattab1,2, Haneen Taweel3, Arein Awad3, Lisa Crump1,2, Pascale Vonaesch4, Jakob Zinsstag1,2, Jan Hattendorf1,2, Niveen M E Abu-Rmeileh3.
Abstract
Background:Campylobacter and Salmonella are the leading causes of foodborne diseases worldwide. Recently, antimicrobial resistance (AMR) has become one of the most critical challenges for public health and food safety. To investigate and detect infections commonly transmitted from animals, food, and the environment to humans, a surveillance-response system integrating human and animal health, the environment, and food production components (iSRS), called a One Health approach, would be optimal. Objective: We aimed to identify existing integrated One Health studies on foodborne illnesses in the Middle East and to determine the prevalence, serovars, and antimicrobial resistance phenotypes and genotypes of Salmonella and Campylobacter strains among humans and food-producing animals.Entities:
Keywords: Campylobacter spp.; Middle East; One Heath; Salmonella spp.; antimicrobial resistance; foodborne pathogens; meta-analysis; systematic review
Year: 2022 PMID: 35625181 PMCID: PMC9137557 DOI: 10.3390/antibiotics11050536
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Search strategy and PRISMA flow diagram.
Figure 2Number of studies (a) per country and (b) per pathogen.
Overall prevalence of Salmonella and Campylobacter and main serotypes.
| Pathogens | No. of Isolated Bacteria from Humans | Total Number of Collected Samples from Humans | The Pooled Prevalence Rate among Humans (%) | No. of Isolated Bacteria from Animals | Total Number of Collected Samples from Animals | The Pooled Prevalence Rate among Animals (%) |
|---|---|---|---|---|---|---|
| 167 | 1317 | 13 | 585 | 3520 | 17 | |
| nontyphoidal | 109 | 1167 | 9 | 352 | 2718 | 13 |
|
| 36 | 780 | 5 | 91 | 3038 | 3 |
|
| 12 | 585 | 2 | 87 | 2534 | 3 |
|
| 435 | 2008 | 22 | 1253 | 4122 | 30 |
|
| 422 | 2693 | 16 | 1182 | 5472 | 22 |
|
| 72 | 1938 | 4 | 367 | 4037 | 9 |
Prevalence of Salmonella and Campylobacter and main serotypes based on the samples sources.
| Pathogens | N (%) Isolated Bacteria from Asymptomatic Humans | Total Number of Asymptomatic Humans Samples | N (%) Isolated Bacteria from Symptomatic Humans | Total Number of Symptomatic from Humans Samples | N (%) Isolated Bacteria from Poultry and Poultry Products | Total Number of Poultry and Poultry Products Samples | N (%) Isolated Bacteria from Ruminants and Ruminant Products | Total Number of Ruminants and Ruminant Products Samples |
|---|---|---|---|---|---|---|---|---|
| 29 (9%) | 342 | 138 (14%) | 975 | 492 (31%) | 1597 | 76 (4%) | 1717 | |
| Nontyphoidal | 11 (6%) | 192 | 98 (10%) | 975 | 259 (33%) | 795 | 76 (4%) | 1717 |
|
| 13 (6%) | 205 | 23 (4%) | 575 | 80 (7%) | 1195 | 9 (0.6) | 1637 |
|
| 1 (2%) | 60 | 11 (2%) | 525 | 82 (9%) | 897 | 5 (0.3) | 1637 |
|
| 28 (14%) | 206 | 407 (23%) | 1802 | 1048 (39%) | 2695 | 205 (10%) | 1427 |
|
| 21 (9%) | 226 | 401 (16%) | 2467 | 968 (25%) | 3894 | 214 (14%) | 1578 |
|
| 18 (8%) | 236 | 54 (3%) | 1702 | 341 (13%) | 2610 | 26 (2%) | 1427 |
Microbial resistance patterns detected by phenotypic screening among non-typhoidal Salmonella.
| Non-Typhoidal | ||||||||
|---|---|---|---|---|---|---|---|---|
| Antibiotic | No. of Resistance Human Isolates | Human Isolates | Resistance Ratio/Human Isolates | No. of Resistance Animal Isolates | Animal Isolates | Resistance Ratio/Animal Isolates | Relative Risk | 95%CI |
| Amoxicillin–Clavulanic acid | 53 | 126 | 42% | 62 | 88 | 70% | 1.09 | [1.01; 1.18] |
| Amoxicillin | 50 | 70 | 71% | 64 | 70 | 91% | 4.02 | [0.16; 103.61] |
| Ampicillin | 97 | 186 | 52% | 96 | 139 | 69% | 1.10 | [0.92; 1.31] |
| Azithromycin | 32 | 75 | 43% | 2 | 22 | 9% | 0.21 | [0.06; 0.82] |
| Cefotaxime | 45 | 145 | 31% | 58 | 92 | 63% | 3 | [0.23; 39.38] |
| Ceftriaxone | 2 | 231 | 1% | 9 | 131 | 7% | 4.33 | [0.93; 20.26] |
| Chloramphenicol | 42 | 281 | 15% | 21 | 181 | 12% | 1.29 | [0.86;1.96] |
| Ciprofloxacin | 26 | 281 | 9% | 30 | 181 | 17% | 1.36 | [0.73; 2.51] |
| Erythromycin | 57 | 57 | 100% | 52 | 52 | 100% | 1 | [0.96; 1.04] |
| Imipenem | 3 | 194 | 2% | 0 | 108 | 0% | 0.45 | [0.05; 4.02] |
| Streptomycin | 50 | 126 | 40% | 38 | 88 | 43% | 1.09 | [0.80; 1.49] |
| Tetracycline | 142 | 231 | 62% | 66 | 131 | 50% | 0.79 | [0.59; 1.06] |
| Trimethoprim–sulfamethoxazole | 67 | 281 | 24% | 15 | 181 | 8% | 0.57 | [0.18; 1.80] |
Microbial resistance patterns detected by phenotypic screening among Campylobacter jejuni.
|
| ||||||||
|---|---|---|---|---|---|---|---|---|
| Antibiotic | No. of Resistance Human Isolates | Human Isolates | Resistance Ratio/Human Isolates | No. of Resistance Animal Isolates | Animal Isolates | Resistance Ratio/Animal Isolates | Relative Risk | 95%CI |
| Amoxicillin–Clavulanic acid | 283 | 416 | 68% | 56 | 173 | 32% | 0.79 | [0.67; 0.95] |
| Amoxicillin | 297 | 297 | 100% | 52 | 52 | 100% | 1 | [0.96; 1.04] |
| Ampicillin | 466 | 579 | 81% | 142 | 223 | 64% | 1 | [0.97; 1.03] |
| Azithromycin | 261 | 297 | 88% | 52 | 52 | 100% | 1.13 | [1.04; 1.24] |
| Chloramphenicol | 258 | 316 | 82% | 50 | 73 | 69% | 1.01 | [0.89; 1.14] |
| Ciprofloxacin | 460 | 627 | 73% | 187 | 265 | 71% | 0.92 | [0.84; 1.01] |
| Erythromycin | 393 | 608 | 65% | 92 | 244 | 38% | 1 | [0.97; 1.03] |
| Nalidixic acid | 558 | 627 | 89% | 201 | 265 | 76% | 0.89 | [0.77; 1.02] |
| Streptomycin | 213 | 544 | 39% | 50 | 235 | 21% | 1.02 | [0.83; 1.26] |
| Tetracycline | 248 | 330 | 75% | 119 | 213 | 56% | 0.94 | [0.84; 1.05] |
| Trimethoprim–sulfamethoxazole | 371 | 399 | 93% | 85 | 103 | 83% | 1.01 | [0.97; 1.04] |
Prevalence of AMR genes found in non-typhoidal Salmonella spp. and Campylobacter jejuni.
| AMR Gen | Study ID | Pathogen | HN | HI | Prevalance_H | AN | AI | Prevalnce_A_ | RR | 95%CI | Lab Technique |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Besharati et al., 2020 and Elhariri et al., 2020 | NTS and S. H | 99 | 13 | 13.13% | 31 | 1 | 3.23% | 0.34 | [0.07; 1.72] | PCR |
|
| Youssef et al., 2021 | NTS | 50 | 8 | 16.00% | 50 | 11 | 22.00% | 1.38 | [0.6; 3.13] | PCR |
|
| Elhariri et al., 2020 | S. H | 24 | 9 | 37.50% | 9 | 1 | 11.11% | 0.3 | [0.04; 2.02] | PCR |
|
| Youssef et al., 2021 | NTS | 50 | 8 | 16.00% | 50 | 11 | 22.00% | 1.38 | [0.6; 3.13] | PCR |
|
| Elhariri et al., 2020 | S. H | 24 | 5 | 20.83% | 9 | 1 | 11.11% | 0.53 | [0.07; 3.96] | PCR |
| PCR | |||||||||||
|
| Divsalar et al., 2019 |
| 80 | 42 | 52.50% | 20 | 7 | 35.00% | 0.67 | [0.35; 1.25] | PCR |
|
| Youssef et al., 2021 and Elhariri et al., 2020 | NTS and S. H | 74 | 14 | 18.92% | 59 | 12 | 20.34% | 1.13 | [0.49; 2.61] | PCR |
|
| Youssef et al., 2021, Besharati et al., 2020 and Elhariri et al., 2020 | NTS, NTS, and S. H | 149 | 19 | 12.75% | 81 | 12 | 14.81% | 0.91 | [0.34; 2.44] | PCR |
|
| Besharati et al., 2020 and AbdEl-Aziz et al., 2020 | NTS and | 223 | 180 | 80.72% | 42 | 29 | 69.05% | 1.04 | [1.01; 1.08] | PCR |
|
| Besharati et al., 2020 | NTS | 75 | 22 | 29.33% | 22 | 6 | 27.27% | 0.93 | [0.43; 2] | PCR |
|
| Divsalar et al., 2019 |
| 80 | 41 | 51.25% | 20 | 7 | 35.00% | 0.68 | [0.36; 1.29] | PCR |
|
| Divsalar et al., 2019 |
| 80 | 17 | 21.25% | 20 | 6 | 30.00% | 1.41 | [0.64; 3.11] | PCR |
|
| Divsalar et al., 2019 and Ghoneim et al., 2020 |
| 84 | 71 | 84.52% | 22 | 17 | 77.27% | 0.92 | [0.73; 1.16] | PCR |
HN: Number of human isolates: HI: human isolates that have this gene; prevalance_H: prevalence among human isolates; AN: number of animal isolates; AI: animal isolates that have this gene; prevalance_A: prevalence among animal isolates; RR: relative risk; NTS: non-typhoidal Salmonella; S.H: Salmonella Heidelberg; C. jejuni: Campylobacter jejuni.